ArticleVeterinary research2026
Different replication behavior of a contemporary porcine hemagglutinating encephalomyelitis virus strain Gent/PS412 compared with the historical neurotropic reference strain VW572.
Article in Veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Porcine hemagglutinating encephalomyelitis virus (PHEV), first identified in 1957, has been described as a neurotropic virus of pigs. However, more recent strains were mainly associated with respiratory problems. This study compared the replication kinetics of the historical neurotropic PHEV strain isolated in Belgium in 1972 (VW572) with the replication kinetics of a contemporary 2020 strain (PS412; isolated from nasal secretions during a monitoring study), using RPD (rein de porc diploid) cells, nasal and ethmoidal mucosa explants, and primary porcine respiratory epithelial cells (PoRECs). EGTA was used to disrupt intercellular junctions to facilitate the access of the virus to basolateral receptors. In RPD cells, VW572 showed an early advantage in initiating infection, whereas PS412 exhibited stronger replication and viral release at later stages, highlighting distinct replication dynamics between the two strains. The replication kinetics of both strains in nasal explants and PoRECs did not differ significantly. In ethmoidal explants, PHEV only replicated in sustentacular cells with VW572 infecting more cells than PS412. EGTA treatment had no effect on the PHEV infection in nasal explants but significantly increased in PoRECs and ethmoidal explants for VW572, suggesting a stronger reliance on basolateral receptors in sustentacular cells. Genomic analysis identified 2 spike protein mutations that led to amino acid changes at the receptor binding site: N512K, K576E. These changes switched the regional polarity on the surface of the spike protein that may affect the PHEV receptor use. In conclusion, the historical and contemporary PHEV isolates VW572 and PS412 replicate differently in the respiratory/neural tissues of the upper respiratory tract which may be associated with amino acid variations in the receptor binding domain of the spike protein.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.